1. For Investors

For | Investors

Progress

  • Closed seed deal with CTM investments LLC.
  • Completed Phase I STTR (RPA).
  • Achieved feasibility milestones.
  • Phase II SBIR application in preparation.
  • Completed Phase I SBIR (XPF).
  • Phase I STTR (XPA) Funded June 1 2015.

Financials

Current

- Angel/Seed investment
  • CTM Investments: $250,000
- NIH Grants to NĒRx BioSciences

Future Needs

- VC/Private Equity
  • Commitment for $3.6M over 3 years
  • FDA filing of Investigational new drug (IND) application for phase 0/1 trial of RPA inhibitors.